AARON Eine offene Phase-II-Studie von Relatlimab (BMS-986016) mit Nivolumab (BMS-936558) in Kombination mit 5-Azacytidin zur Behandlung von Patienten mit refraktärer/rezidivierter akuter myeloischer Leukämie und neu diagnostizierten älteren Patienten mit akuter myeloischer Leukämie (Aktiv)
ADVANCE II A study to evaluate the safety and efficacy of a dendritic cell based vaccination treatment aimed to stimulate the immune system to eradicate remaining residual disease (Aktiv)
AMoRe2017 Study to treat the molecular relapsed of AML patients in childhood with Azacitidine (Aktiv)
CHDM201H12101C HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (Aktiv)
HaploMUD Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis (Aktiv)
HaploMUDStudy Phase II Studie zu Spendertypen für die allogene Stammzelltransplantation bei akuter Leukämie (Aktiv)
NIFAR Phase 1/2 trial to test Nivolumab in treatment failure of Acute Myeloid Leukemia (AML) after stem cell transplantation by a allogenic donor (allo-SCT) (Aktiv)
PALOMA Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML (PALOMA) (Aktiv)
PEMAZA MRD-guided Treatment in NPM1mut AML Patients (PEMAZA) (Aktiv)
TEAM TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (TEAM) (Aktiv)
TUD-APOLLO-064 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064) (Aktiv)
Erstlinie
AMLSG 24-15 Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 (Aktiv)
AMLSG 28-18 / HOVON 156 AML A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (Aktiv)
AMLSG 29-18 / HOVON 150 A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (Aktiv)
AMLSG 30-18 Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics (Aktiv)
AMLSG 31-19 / HOVON 501 Eine randomisierte, placebokontrollierte Phase-III-Studie zur Induktions- und Konsolidierungs-Chemotherapie mit Venetoclax bei erwachsenen Patienten mit neu diagnostizierter akuter myeloischer Leukämie oder myelodysplastischem Syndrom mit Blastenüberschuss-2 (Aktiv)
Abbvie M20-866 Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome (Aktiv)
DaunoDouble Randomisierter Vergleicher zwischen zwei Dosierungen von Daunorubicin und zwischen Einfach- und Doppel-Induktionstherapie bei erwachsenen Patienten mit Akuter Myeloischer Leukämie ≤ 60 Jahre (Aktiv)
MOSAIC Addition of midostaurin and gemtuzumab ozogamicin to standard chemotherapy with cytarabine and daunorubicin in patients with newly diagnosed acute myeloid leukemia (Aktiv)
NAPOLEON National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup (Aktiv)
STIMULUS-AML1 (CMBG453C12201) A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy (Aktiv)
TUD-MOSAIC-075 Phase I/II Studie zu Midostaurin und Gemtuzumab Ozogamicin bei neu diagnostizierter akuter myeloischer Leukämie (Aktiv)
WINK (SMS-0341_WiNK) A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia (Aktiv)
AMG 330 A Phase 1 First-in-human Study Evaluating AMG 330 Administered as Continuous Intravenous Infusion (Aktiv)
AMG427 Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (Aktiv)
AMLSG 23-14 Study of Palbociclib in MLL-rearranged Acute Leukemias (Aktiv)
DART-Studie (CP-MGD006-01) A Phase 1/2 Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome (Aktiv)
DOSE ESCALATION OF RO7283420 IN AML EINE OFFENE, MULTIZENTRISCHE PHASE-I-STUDIE ZUR BEURTEILUNG DER SICHERHEIT, VERTRÄGLICHKEIT, PHARMAKOKINETIK UND PHARMAKODYNAMIK VON RO7283420 ALS EINZELWIRKSTOFF BEI HÄMATOLOGISCH UND MOLEKULAR REZIDIVIERTER/REFRAKTÄRER AKUTER MYELOISCHER LEUKÄMIE (Aktiv)
GEM333-01 Phase I Studie zu GEM333 bei rezidivierter oder refraktärer akuter myeloischer Leukämie (Aktiv)
H3 Biomedicine Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (Aktiv)
IMGN632-0802 A study of IMGN632 alone or in combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia (Aktiv)
M13-833 A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies (Aktiv)
PONS Ponatinib for Treatment of Patients with CP-CML after treatment with other TKI has failed (Aktiv)
Q-HAM Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD (Aktiv)
RELAX (AML) Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) (Aktiv)
UC02-123-01 Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies (Aktiv)